UroGen Pharma Ltd. (URGN)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Elizabeth A. Barrett | President, CEO & Director | 1.12M | -- | 1962 |
| Mr. Dong Kim | Chief Financial Officer | 546.68k | -- | 1977 |
| Mr. Jason Drew Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | 717.58k | -- | 1972 |
| Vincent I. Perrone | Senior Director of Investor Relations | -- | -- | -- |
| Mr. Bryon Wornson | Executive Vice President of Talent, Advocacy & Communications | -- | -- | -- |
| Dr. Sari Prutchi-Sagiv Ph.D. | Marketing Director | -- | -- | -- |
| Dr. Marina Konorty | Executive Vice President of Research & Development and Technical Operations | -- | -- | -- |
| Dr. Mark P. Schoenberg M.D. | Chief Medical Officer | 579.5k | -- | 1958 |
| Mr. Jeffrey Bova M.B.A. | Chief Commercial Officer | -- | -- | -- |
| Mr. James Ottinger R.ph. | Executive Vice President of Regulatory Affairs & Quality | -- | -- | -- |
UroGen Pharma Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 198
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Corporate Governance
Recent Events
- Mar 14, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 04, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 01, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 07, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 17, 20248-K: Corporate Changes & Voting MattersSee Full Filing